New Alzheimer’s Protocol Seeks to Slow Progression, Even Reverse Disease

From: Epigenesis Corporation
Published: Thu Jan 19 2017


Prescott, AZ -- Every three seconds, someone in the world is diagnosed with Alzheimer’s related dementia. Arizona-based Epigenesis Corporation hopes to use $100 million dollars in grant funding from the MacArthur Foundation to address this worldwide health crisis.

Epigenesis, based in Prescott, Arizona, is amongst the first Global organizations designed to capture, curate and disseminate academic, scientific and user friendly research and applications in the new science of Epigenetics; the study of internal, biological mechanisms that switch genes, including those carrying disease, on or off.

Comprised of therapists, health-care practitioners, scientists and healers experienced in chronic and long-lasting illnesses, Epigenesis Corporation’s guiding mission and vision is to help those who have or who may get Alzheimer’s disease to lead healthier, more fulfilling lives.

"Our proprietary Alzheimer’s mitigation protocol is currently the foundation of our work, but we are poised to release protocols that target cancer, heart disease and other forms of cognitive-neuro disorders including autism and other chronic illnesses," says Dr. Barry Spiker, founder and CEO.

Their impressive entry into MacArthur’s prestigious 100&Change grant competition is a proposal to use their Alzheimer’s mitigation protocol, BEEMS™, to disrupt or delay the progress of the disease and provide potential solutions for sufferers around the world, long before they become too debilitated to function volitionally and rationally.

The BEEMS Protocol™ (Body, Emotion, Environment, Mind and Spirit) is a series of lifestyle and body-mind interventions that utilizes a comprehensive set of guidelines derived from the best and latest of clinically relevant research shown to potentially delay or avoid the onset of Alzheimer’s disease. Beginning with an assessment of risk for developing Alzheimer’s, anyone may access the services to guide them through the best-understood set of interventions that could potentially prevent or slow progression of the disease. An in-depth, multi-disciplinary protocol is developed specifically for that patient who is then paired with a team of professionals to personally work with them. Patient progress is tracked and entered into a database as research and evidence for future protocols.

Boosting Epigenesis Corporation’s chances of taking home the prize are the dismal and disheartening statistics on Alzheimer’s disease. Worldwide, over 46 million people currently suffer from the affliction, or related mental health issues, and by 2050 that number is expected to hit 131.5 million sufferers. With nearly 6 million patients residing in the United States alone, and with as many as 10 million un- or misdiagnosed cases, Alzheimer’s is considered by many in the medical profession to be the 3rd leading cause of death in the United States today.

The average cost of providing care for someone with Alzheimer's is nearly $60,000 a year, with private nursing homes costing more than $82,000 per year, on average. Over the life of the disease, which is often between eight and ten years, patients can expect to spend in excess of $500,000 dollars. As populations age globally, in just three years, the worldwide economic cost will exceed $1 trillion USD.

"There is no cure for Alzheimer’s," adds Spiker. "But, perhaps there is a way to give millions of sufferers, around the world, new hope for a longer life with a more improved quality than most of them have today," "Epigenesis Corp, it’s staff and its supporters have staked their future on providing that way."
Company: Epigenesis Corporation
Contact Name: prjacqui
Contact Email: jacqui@knightowlpr.com
Contact Phone: 678-926-3257

Visit website »